| Virksomhedsstatus | | UNDER KONKURS. |
| Sidst opdateret den 15.01.2021 og
angivet som gældende fra 11.01.2021 (1407
dage). |
| Historik | Start | Stop |
|---|
| UNDER KONKURS | 11.01.2021 | |
| UNDER TVANGSOPLØSNING | 22.09.2020 | 10.01.2021 |
| NORMAL | 12.12.2000 | 21.09.2020 |
| Branche | | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
| Sidst opdateret den 23.12.2007 og
angivet som gældende fra 01.01.2008 (6166
dage). |
| Historik | Start | Stop |
|---|
| Forskning og eksperimentel udvikling indenfor bioteknologi (721100) | 01.01.2008 | |
| Forskning og udvikling inden for naturvidenskab og teknik (731000) | 17.10.2002 | 31.12.2007 |
| Offentlig administration af sundhedsvæsen, undervisning og sociale forhold (751200) | 12.12.2000 | 16.10.2002 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 09.05.2001 (8594
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | ENKAM PHARMACEUTICALS ApS. |
| Sidst opdateret den 31.05.2018 og
angivet som gældende fra 31.05.2018 (2363
dage). |
| Historik | Start | Stop |
|---|
| ENKAM PHARMACEUTICALS ApS | 31.05.2018 | |
| ENKAM PHARMACEUTICALS A/S | 30.03.2001 | 30.05.2018 |
| ENKAM PHARMACEUTICALS ApS | 12.12.2000 | 29.03.2001 |
| Binavne | | ENKAM ApS. |
| Sidst opdateret den 31.05.2018 og
angivet som gældende fra 31.05.2018 (2363
dage). |
| Historik | Start | Stop |
|---|
| ENKAM ApS | 31.05.2018 | |
| ENKAM PHARMA ApS | 31.05.2018 | |
| ENKAM A/S | 09.05.2001 | 30.05.2018 |
| ENKAM PHARMA A/S | 09.05.2001 | 30.05.2018 |
| Historik | Start | Stop |
|---|
| Virksomheden tegnes af en likvidator | 23.11.2020 | 11.01.2021 |
| Selskabet tegnes af en direktør | 31.05.2018 | 22.09.2020 |
| Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af en direktør i forening med to bestyrelsesmedlemmer eller af den samlede bestyrelse, | 31.05.2013 | 30.05.2018 |
Ingen nuværende registrering.
Type af revisorbistand:Revisionspåtegning
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):As discussed in Note 1 to the financial statements, ENKAM Pharmaceuticals ApS’s liabilities exceed it’s assets, and consequently the Company risks a bankruptcy if an agreement is not entered into with the Company's creditors and additional funds are obtained from the Company's shareholders. Based on the audit evidence obtained, we believe that ENKAM Pharmaceuticals ApS will not be able to meet its obligations in the ordinary course of business. Accordingly, we do not agree with management’s preparation and presentation of the financial statements on a going concern basis. The financial statements do not include the adjustments that would result, if the financial statements had been prepared based on liquidation accounting.
We conducted our audit in accordance with International Standards on Auditing (ISAs) and the ad-ditional requirements applicable in Denmark. Our responsibilities under those standards and re-quirements are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evi-dence we have obtained is sufficient and appropriate to provide a basis for our adverse opinion.
Konklusion (revision):Because of the significance of the matter discussed in the basis for adverse opinion paragraph, the financial statements do not present fairly, the financial position of ENKAM Pharmaceuticals ApS as at 31 December 2018, and its financial performance for the financial year 1 January – 31 December 2018 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for Management’s Review.
Our opinion on the Financial Statements døs not cover Management’s Review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the Financial Statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financials Statements Act.
As stated in the section Basis for Adverse Opinion, our opinion on the financial statements has been modified as a result of the Company risks a bankruptcy if an agreement is not entered into with the Company's creditors and additional funds are obtained from the Company's shareholders. We have concluded that, for the same reason, the Management's Review contains material misstatement in relation to the lack of information of the adjustments that would result, if the financial statements had been prepared based on liquidation accounting.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration